文献速递眼底病与葡萄膜炎

玻璃体腔注射法瑞西单抗后出现严重眼内炎症

Severe Intraocular Inflammation Following Intravitreal Faricimab.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

本病例系列报告了同一机构在2023年9月20日至10月20日期间发生的3例玻璃体腔注射法瑞西单抗后急性严重眼内炎症,患者既往接受过阿柏西普治疗,注射后3至4天出现前节和后节炎症,玻璃体穿刺培养均为阴性,症状在1个月内缓解,作者认为这一聚集性事件提示此类炎症事件可能比法瑞西单抗试验报告中所预期的更常见。

要点

  • 3例患者玻璃体腔注射法瑞西单抗后3至4天出现急性严重眼内炎症,累及前节和后节。
  • 所有玻璃体穿刺培养结果均为阴性,1例玻璃体切除标本培养出1个表皮葡萄球菌菌落,感染病专家判断可能为污染。
  • 所有症状在1个月内缓解,最佳矫正视力分别恢复至20/100、20/50和20/30。

核心结论

  • 作者认为这一聚集性事件提示玻璃体腔注射法瑞西单抗后的炎症事件可能比法瑞西单抗试验报告中所预期的更常见,强调在监管批准后持续保持警惕以发现和报告此类病例的必要性。

研究设计与样本

  • 本病例系列在单一机构内识别了3例在玻璃体腔注射法瑞西单抗后出现急性严重眼内炎症的患者,发生时间为2023年9月20日至2023年10月20日。

主要发现

  • 3例患者均接受了玻璃体腔注射法瑞西单抗6 mg(0.05 mL的120 mg/mL溶液),来自2个不同批号(有效期至2025年7月),由同一机构3个不同地点的3名视网膜专科医生(共19名视网膜专科医生)实施注射。
  • 注射前最佳矫正视力分别为患者1左眼20/63、患者2右眼20/40、患者3左眼20/20;注射后3至4天内全部出现累及前节和后节的急性严重炎症,视力分别为左眼手动、右眼数指、左眼手动。
  • 所有患者玻璃体穿刺培养结果均为阴性;1例患者在就诊后1天接受玻璃体切除术,术中玻璃体培养长出1个表皮葡萄球菌菌落,感染病专家判断可能为污染。
  • 所有症状在1个月内缓解,最佳矫正视力分别为患者1左眼20/100、患者2右眼20/50、患者3左眼20/30。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Monitoring for and reporting potential cases of intraocular inflammation (IOI) in clinical practice despite limited occurrences in clinical trials, including experiences with relatively new intravitreal agents, such as brolucizumab, pegcetacoplan, or faricimab, helps balance potential benefits and risks of these agents. OBJECTIVE: To provide descriptions of 3 initially culture-negative cases of acute, severe, posterior-segment IOI events occurring within the same month following intravitreal faricimab injections at a single institution. DESIGN, SETTING, AND PARTICIPANTS: In this case series, 3 patients manifesting acute, severe IOI following intravitreal injection of faricimab were identified between September 20, 2023, and October 20, 2023. EXPOSURE: Faricimab, 6 mg (0.05 mL of 120 mg/mL solution), for neovascular age-related macular degeneration among patients previously treated with aflibercept; 1 patient also had prior exposure to bevacizumab. MAIN OUTCOMES AND MEASURES: Visual acuity, vitreous taps for bacterial or fungal cultures, and retinal imaging. RESULTS: All 3 patients received intravitreal faricimab injections between September 20 and October 20, 2023, from 2 different lot numbers (expiration dates, July 2025) at 3 locations of 1 institution among 3 of 19 retina physicians. Visual acuities with correction were 20/63 OS for patient 1, 20/40 OD for patient 2, and 20/20 OS for patient 3 prior to injection. All 3 patients developed acute, severe inflammation involving the anterior and posterior segment within 3 to 4 days after injection, with visual acuities of hand motion OS, counting fingers OD, and hand motion OS, respectively. Two patients were continuing faricimab treatment while 1 patient was initiating faricimab treatment. All received intravitreal ceftazidime, 2.2 mg/0.1 mL, and vancomycin, 1 mg/0.1 mL, immediately following vitreous taps. All vitreous tap culture results were negative. One patient underwent vitrectomy 1 day following presentation. Intraoperative vitreous culture grew 1 colony of Staphylococcus epidermidis, judged a likely contaminant by infectious disease specialists. All symptoms resolved within 1 month; visual acuities with correction were 20/100 OS for patient 1, 20/50 OD for patient 2, and 20/30 OS for patient 3. CONCLUSIONS AND RELEVANCE: In this case series, 3 patients with acute, severe IOI within 1 month at 3 different locations among 3 ophthalmologists of 1 institution following intravitreal faricimab could represent some unknown storage or handling problem. However, this cluster suggests such inflammatory events may be more common than anticipated from faricimab trial reports, emphasizing the continued need for vigilance to detect and report such cases following regulatory approval.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Thangamathesvaran L, Kong J, Bressler SB, et al. Severe Intraocular Inflammation Following Intravitreal Faricimab. JAMA Ophthalmol. 2024. PMID: 38421861. doi:10.1001/jamaophthalmol.2024.0530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。